Progress with COVID vaccine development and implementation

Affiliations

¹ Department of Biosciences, University of Exeter, Devon, UK. R.W.Titball@exeter.ac.uk.
² Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.
³ Nature Research, London, UK.
⁴ Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.
⁵ CIRI - Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, CIC 1408 Vaccinology, F42023, Saint-Etienne, France.
⁶ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁷ Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
⁸ Department of Medical Microbiology and Infection Prevention, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁹ Federal Ministry of Education and Research, Berlin, Germany.
¹⁰ Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
¹¹ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.

Editorial

Richard W Titball et al. NPJ Vaccines. 2024.

. 2024 Apr 1;9(1):69.

doi: 10.1038/s41541-024-00867-3.

¹ Department of Biosciences, University of Exeter, Devon, UK. R.W.Titball@exeter.ac.uk.
² Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.
³ Nature Research, London, UK.
⁴ Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.
⁵ CIRI - Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, CIC 1408 Vaccinology, F42023, Saint-Etienne, France.
⁶ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁷ Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
⁸ Department of Medical Microbiology and Infection Prevention, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁹ Federal Ministry of Education and Research, Berlin, Germany.
¹⁰ Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
¹¹ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.

No abstract available

Conflict of interest statement

R.W.T., D.I.B., N.V.J.F., R.A.H., S.L., P.M., R.R., M.vG., V.v.M., D.H.W. and A.D.T.B. are editors for NPJ Vaccines.

1. Division, U. S. COVID-19 Market Dashboardhttps://www.unicef.org/supply/covid-19-market-dashboard. (2024)
1. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. doi: 10.1038/s41541-021-00292-w. - DOI - PMC - PubMed
1. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6:74. doi: 10.1038/s41541-021-00336-1. - DOI - PMC - PubMed
1. Zhang L, et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines. 2023;8:156. doi: 10.1038/s41541-023-00751-6. - DOI - PMC - PubMed
1. Krauson AJ, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. NPJ Vaccines. 2023;8:141. doi: 10.1038/s41541-023-00742-7. - DOI - PMC - PubMed